TNF and rheumatoid arthritis: Furthermore, a recent post-marketing safety survey, the ORAL surveillance study, raised concerns about an increased risk of malignancies and major adverse cardiovascular events associated with tofacitinib, compared with tumor necrosis factor inhibitors, in patients with RA with particular risk factors [8].